Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Have gravitational waves provided the first hint of primordial black holes born during the Big Bang? - 2Select Your Cherished Fish
- 3Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 4New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- 5Manual for 6 famous sorts of cheddar
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- Why screening for the deadliest cancer in the U.S. misses most cases
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- Find the Captivating Professional flowerbeds of the US
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Pick Your Favored kind of soup
